Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Holding(s) in Company

3 Aug 2009 14:05

RNS Number : 7744W
Celsis International PLC
03 August 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Celsis International Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 Barclays PLC

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 30-Jul-09

6. Date on which issuer notified:

 31-Jul-09

7. Threshold(s) that is/are crossed or reached:

 5% to below notifiable %

  

8. Notified details:

A: Voting rights attached to shares

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 

 1,103,729

 1,103,729

Not Reportable

 Not Reportable

 Not Reportable

 Not Reportable

 Not Reportable

 GB00B0CD5F69

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

 

 

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

Not Reportable

 

Not Reportable

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

 

14. Contact name:

 Geoff Smith

15. Contact telephone number:

 020 7116 2913

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOSURKKRWRAR
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.